1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsTechnology Development to Reduce Health Disparities (R01 Clinical Trial Optional) is sponsored by National Institutes of Health. Supports the development and translation of medical technologies aimed at reducing health disparities among racial and ethnic minorities, socioeconomically disadvantaged individuals, and medically underserved populations.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional) | Research Funding National Institutes of Health Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) encourages grant applications to develop and translate medical technologies aimed at reducing disparities in healthcare access and health outcomes.
Appropriate medical technologies should be effective, affordable, culturally acceptable, and deliverable to those who need them. Application Due Dates: Feb. 11, 2022; Jan.
26, 2023; May 31, 2023; Jan. 26, 2024; January 21, 2025 AIDS Due Dates: May 2, 2022; May 2, 2023; Sep.
6, 2023; May 2, 2024; May 02, 2025 RFA-EB-21-001 Expiration Date: New Date May 03, 2025 (Original Date: May 03, 2024) per issuance of NOT-EB-24-002 This NOSI is intended to encourage interest in the small business community to develop various approaches, technologies, and tools to address the health issues of maternal morbidity and mortality by achieving a wide array of outcomes, such as 1) the identification, phenotyping, subtyping, and stratification of patients at a greater risk of MMM, 2) multi-level interventions to address racial disparities in MMM, and 3) clinical decision-making that considers social and cultural biases.
Furthermore, this NOSI focuses on the development and validation of tools, technologies, and approaches, including artificial intelligence (AI) and machine learning, that indicate states of increased risk for and presence of MMM.
This includes but is not limited to development of tools and technologies that: Measure factors associated with increased risk for MMM, including but not limited to blood pressure, heart rate, maternal/fetal physiology, or pupil dilation and facial expression. Measure biometrics associated with the onset and exacerbation of various diseases of MMM, including but not limited to depression or preeclampsia.
Predict risk from a variety of data sources, for example, medical charts and electronic health records. Alert patients and clinicians to potential risk factors. Suggest various prevention and treatment approaches.
Application budgets are limited to $500,000 direct costs annually, not including consortia F&A. Award Project Period: Four years Engineering and Physical Sciences Medical - Clinical Science
According to the current listing, eligibility includes: Nonprofits, For-profits, Universities, State/local governments, Individuals. Confirm the full requirements in the official notice before applying.
Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional) is funded by National Institutes of Health. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article